UY28868A1 - Ácidos heterociclilacéticos como inhibidores de tafla. - Google Patents

Ácidos heterociclilacéticos como inhibidores de tafla.

Info

Publication number
UY28868A1
UY28868A1 UY28868A UY28868A UY28868A1 UY 28868 A1 UY28868 A1 UY 28868A1 UY 28868 A UY28868 A UY 28868A UY 28868 A UY28868 A UY 28868A UY 28868 A1 UY28868 A1 UY 28868A1
Authority
UY
Uruguay
Prior art keywords
heterociclilacétic
acids
inhibitors
tafla inhibitors
compounds
Prior art date
Application number
UY28868A
Other languages
English (en)
Spanish (es)
Inventor
Dr Andreas Lindenschmidt
Dr Christopher Kallus
Dr Holger Heitsch
Dr Sven Grueneberg
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34964308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY28868(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of UY28868A1 publication Critical patent/UY28868A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
UY28868A 2004-04-22 2005-04-22 Ácidos heterociclilacéticos como inhibidores de tafla. UY28868A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004020186A DE102004020186A1 (de) 2004-04-22 2004-04-22 Heterocyclylessigsäuren als Inhibitoren von TAFla

Publications (1)

Publication Number Publication Date
UY28868A1 true UY28868A1 (es) 2005-11-30

Family

ID=34964308

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28868A UY28868A1 (es) 2004-04-22 2005-04-22 Ácidos heterociclilacéticos como inhibidores de tafla.

Country Status (34)

Country Link
EP (2) EP1864979B1 (enExample)
JP (1) JP4939401B2 (enExample)
KR (1) KR101162047B1 (enExample)
CN (1) CN100572376C (enExample)
AR (1) AR053302A1 (enExample)
AT (2) ATE386737T1 (enExample)
AU (1) AU2005238144B2 (enExample)
BR (1) BRPI0510159A (enExample)
CA (1) CA2563401C (enExample)
CR (1) CR8650A (enExample)
CY (1) CY1108087T1 (enExample)
DE (2) DE102004020186A1 (enExample)
DK (1) DK1740569T3 (enExample)
EC (1) ECSP066941A (enExample)
ES (1) ES2299026T3 (enExample)
HR (1) HRP20080099T3 (enExample)
IL (1) IL178672A (enExample)
MA (1) MA28543B1 (enExample)
MY (1) MY140903A (enExample)
NI (1) NI200600217A (enExample)
NO (1) NO20065320L (enExample)
NZ (1) NZ550757A (enExample)
PE (1) PE20060172A1 (enExample)
PL (1) PL1740569T3 (enExample)
PT (1) PT1740569E (enExample)
RS (1) RS50553B (enExample)
RU (1) RU2375356C2 (enExample)
SI (1) SI1740569T1 (enExample)
TN (1) TNSN06341A1 (enExample)
TW (1) TWI359016B (enExample)
UA (1) UA87306C2 (enExample)
UY (1) UY28868A1 (enExample)
WO (1) WO2005105781A1 (enExample)
ZA (1) ZA200607668B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0720241A2 (pt) 2006-12-06 2013-12-31 Sanofi Aventis Derivados de ureia e sulfamida como inibidores de tafia
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
EP2142538B1 (en) * 2007-02-13 2011-10-26 Schering Corporation Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists
US8183381B2 (en) * 2007-07-19 2012-05-22 Metabolex Inc. N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
WO2009103432A2 (en) * 2008-02-21 2009-08-27 Sanofi-Aventis Covalently binding imaging probes
UA104002C2 (ru) 2008-06-06 2013-12-25 Санофи-Авентис МАКРОЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ МОЧЕВИНЫ И СУЛЬФАМИДА КАК ИНГИБИТОРЫ TAFIa
WO2010050525A1 (ja) 2008-10-29 2010-05-06 大正製薬株式会社 ＴＡＦＩａ阻害活性を有する化合物
RS52963B (sr) * 2009-05-15 2014-02-28 Sanofi Postupak za dobijanje jedinjenja koje je korisno kao inhibitor tafia
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2483281B1 (en) 2009-10-01 2014-06-04 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
CN102803226B (zh) * 2010-03-18 2016-05-04 第一三共株式会社 环烷基取代的咪唑衍生物
WO2011115065A1 (ja) 2010-03-18 2011-09-22 第一三共株式会社 シクロプロパンカルボン酸誘導体
CN103201269A (zh) 2010-11-11 2013-07-10 赛诺菲 3-(6-氨基-吡啶-3基)-2-丙烯酸衍生物的制备方法
EP2782575B1 (en) 2011-11-25 2016-04-20 Sanofi Crystalline salts of r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid
US9102657B2 (en) * 2011-11-25 2015-08-11 Sanofi Sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid
WO2013076177A1 (de) 2011-11-25 2013-05-30 Sanofi Salz von (r)-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1h-imidazol-4-yl)- propionsäureethylester
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
JP6461113B2 (ja) 2013-06-10 2019-01-30 サノフイＳａｎｏｆｉ ＴＡＦＩａの阻害剤としての大環状尿素誘導体、それらの製造および医薬としての使用
WO2017170460A1 (ja) 2016-03-29 2017-10-05 第一三共株式会社 炎症性腸疾患治療剤
AU2017305392A1 (en) 2016-08-03 2019-02-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1142879B1 (en) * 1998-12-24 2007-10-10 Astellas Pharma Inc. Imidazole compounds and medicinal use thereof
WO2003013526A1 (en) 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
BR0307033A (pt) 2002-01-22 2004-12-07 Pfizer ácidos 3-(imidazolil)-2-aminopropanóicos para o uso como inibidores tafi-a para o tratamento de doenças trombóticas

Also Published As

Publication number Publication date
UA87306C2 (en) 2009-07-10
EP1864979B1 (de) 2011-09-07
EP1864979A1 (de) 2007-12-12
TNSN06341A1 (en) 2008-02-22
KR101162047B1 (ko) 2012-07-04
PL1740569T3 (pl) 2008-07-31
TW200602325A (en) 2006-01-16
AU2005238144B2 (en) 2010-08-26
KR20070007346A (ko) 2007-01-15
ZA200607668B (en) 2008-03-26
CY1108087T1 (el) 2014-02-12
MY140903A (en) 2010-01-29
JP2007533672A (ja) 2007-11-22
CR8650A (es) 2007-12-04
NO20065320L (no) 2007-01-12
AR053302A1 (es) 2007-05-02
EP1740569A1 (de) 2007-01-10
RU2006141246A (ru) 2008-06-10
BRPI0510159A (pt) 2007-10-02
SI1740569T1 (sl) 2008-06-30
RS50553B (sr) 2010-05-07
EP1740569B1 (de) 2008-02-20
PT1740569E (pt) 2008-03-31
ATE386737T1 (de) 2008-03-15
ATE523505T1 (de) 2011-09-15
TWI359016B (en) 2012-03-01
MA28543B1 (fr) 2007-04-03
IL178672A (en) 2011-08-31
CN100572376C (zh) 2009-12-23
CN1950357A (zh) 2007-04-18
CA2563401C (en) 2012-08-07
DE502005002927D1 (de) 2008-04-03
HRP20080099T3 (en) 2008-03-31
DE102004020186A1 (de) 2005-11-17
HK1101823A1 (zh) 2007-10-26
ES2299026T3 (es) 2008-05-16
CA2563401A1 (en) 2005-11-10
ECSP066941A (es) 2006-12-20
DK1740569T3 (da) 2008-06-02
AU2005238144A1 (en) 2005-11-10
JP4939401B2 (ja) 2012-05-23
RU2375356C2 (ru) 2009-12-10
IL178672A0 (en) 2007-02-11
WO2005105781A1 (de) 2005-11-10
NZ550757A (en) 2010-06-25
PE20060172A1 (es) 2006-03-31
NI200600217A (es) 2008-06-17

Similar Documents

Publication Publication Date Title
UY28868A1 (es) Ácidos heterociclilacéticos como inhibidores de tafla.
CO6321271A2 (es) Derivados de urea macrociclicos y de sulfamida como inhibidores de tafla
MX2018005925A (es) Purinonas como inhibidores de proteasa específica de ubiquitina 1.
PH12019501611A1 (en) Chemical compounds as inhibitors of interleukin-1 activity
BRPI0510777A (pt) indazóis substituìdos, composições que os contêm, processo de produção e utilização
CR20190394A (es) Compuestos de inhibidores de autotaxina
CR20110103A (es) Heteroarilos sustituidos
CO6390069A2 (es) Compuestos de piridina sustituida unida por puente a un heterociclo, como inhibidores de la vía de señalización hedgehog.
UY31170A1 (es) Compuestos moduladores de sirtuina
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
MX2015011281A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
ECSP077296A (es) Fenilaminotiazoles sustituidos y su uso
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
GT201200293A (es) Marcadores predictivos útiles en el tratamiento del síndrome frágil x (fxs)
CL2011002911A1 (es) Compuestos derivados de benzamidas, inhibidores de serina proteasa; composición farmacéutica; uso del compuesto para tratar cáncer.
CL2015002583A1 (es) Composiciones aglomerantes y métodos para fabricación y uso de las mismas.
CY1116384T1 (el) Παραγωγα σουλφαμιδιου ως αναστολεις tafia
MX390446B (es) Un dispositivo para la distribucion uniforme de lechadas.
DOP2007000142A (es) Derivados de urea y derivados de sulfamida en calidad de inhibidores de tafia
UY30760A1 (es) Derivados de urea y derivados de sulfamida en calidad de inhibidores de tafia
BR112017003889A2 (pt) variantes de inibidor de tecido de metaloproteinase tipo três (timp-3), composições e métodos
RU2009104276A (ru) Антиульцерогенное средство
AR060934A1 (es) Uso de un activador de plasminogeno para la manufactura de un medicamento para el tratamiento de tromboembolismo venoso
UY31628A1 (es) Triazolopiridazinas como inhibidores de par1, su preparación y su uso como medicamentos
BR112017027813A2 (pt) conjugados de agente de ligação-droga (adcs) e conjugados de agente de ligação-pró-droga (apdcs) tendo grupos enzimaticamente cliváveis